Katie Nason to Esophageal Neoplasms
This is a "connection" page, showing publications Katie Nason has written about Esophageal Neoplasms.
Connection Strength
6.879
-
Lu M, Luketich JD, Levy RM, Awais O, Sarkaria I, Visintainer P, Nason KS. Anastomotic complications after esophagectomy: Influence of omentoplasty in propensity-weighted cohorts. J Thorac Cardiovasc Surg. 2020 05; 159(5):2096-2105.
Score: 0.588
-
Tam V, Luketich JD, Winger DG, Sarkaria IS, Levy RM, Christie NA, Awais O, Shende MR, Nason KS. Cancer Recurrence After Esophagectomy: Impact of Postoperative Infection in Propensity-Matched Cohorts. Ann Thorac Surg. 2016 Nov; 102(5):1638-1646.
Score: 0.465
-
Nason KS. Improving Quality: When Surgeons Take the Bit Between the Teeth, Patients Win! Semin Thorac Cardiovasc Surg. 2016; 28(1):170-1.
Score: 0.454
-
Davison JM, Landau MS, Luketich JD, McGrath KM, Foxwell TJ, Landsittel DP, Gibson MK, Nason KS. A Model Based on Pathologic Features of Superficial Esophageal Adenocarcinoma Complements Clinical Node Staging in Determining Risk of Metastasis to Lymph Nodes. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):369-377.e3.
Score: 0.444
-
Nason KS. Minimal or maximal surgery for esophageal cancer? J Thorac Cardiovasc Surg. 2016 Mar; 151(3):633-635.
Score: 0.442
-
Zahoor H, Luketich JD, Weksler B, Winger DG, Christie NA, Levy RM, Gibson MK, Davison JM, Nason KS. The revised American Joint Committee on Cancer staging system (7th edition) improves prognostic stratification after minimally invasive esophagectomy for esophagogastric adenocarcinoma. Am J Surg. 2015 Oct; 210(4):610-7.
Score: 0.433
-
Zahoor H, Luketich JD, Levy RM, Awais O, Winger DG, Gibson MK, Nason KS. A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma. J Thorac Cardiovasc Surg. 2015 Feb; 149(2):538-47.
Score: 0.413
-
Nason KS. Predicting response to neoadjuvant therapy in esophageal cancer with p53 genotyping: a fortune-teller's crystal ball or a viable prognostic tool? J Thorac Cardiovasc Surg. 2014 Nov; 148(5):2286-7.
Score: 0.411
-
Nason KS. Invited commentary. Ann Thorac Surg. 2014 Feb; 97(2):453.
Score: 0.393
-
Davison JM, Ellis ST, Foxwell TJ, Luketich JD, Gibson MK, Kuan SF, Nason KS. MUC2 expression is an adverse prognostic factor in superficial gastroesophageal adenocarcinomas. Hum Pathol. 2014 Mar; 45(3):540-8.
Score: 0.387
-
Nason KS, Wichienkuer PP, Awais O, Schuchert MJ, Luketich JD, O'Rourke RW, Hunter JG, Morris CD, Jobe BA. Gastroesophageal reflux disease symptom severity, proton pump inhibitor use, and esophageal carcinogenesis. Arch Surg. 2011 Jul; 146(7):851-8.
Score: 0.329
-
Bao C, Tourdot RW, Brunette GJ, Stewart C, Sun L, Baba H, Watanabe M, Agoston AT, Jajoo K, Davison JM, Nason KS, Getz G, Wang KK, Imamura Y, Odze R, Bass AJ, Stachler MD, Zhang CZ. Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma. Nat Commun. 2023 10 04; 14(1):6203.
Score: 0.192
-
Lowenthal BM, Nason KS, Pennathur A, Luketich JD, Pai RK, Davison JM, Ma C. Loss of ARID1A expression is associated with DNA mismatch repair protein deficiency and favorable prognosis in advanced stage surgically resected esophageal adenocarcinoma. Hum Pathol. 2019 12; 94:1-10.
Score: 0.146
-
Birkness JE, Spada NG, Miller C, Luketich JD, Nason KS, Sun W, Davison JM. Extreme chromosome 17 copy number instability is a prognostic factor in patients with gastroesophageal adenocarcinoma: A retrospective cohort study. Genes Chromosomes Cancer. 2018 01; 57(1):28-34.
Score: 0.127
-
Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui U, Gelrud A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinsson V, Lee J, Bass AJ, Catenacci DV. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 01; 8(1):37-48.
Score: 0.127
-
Dhupar R, Van Der Kraak L, Pennathur A, Schuchert MJ, Nason KS, Luketich JD, Lotze MT. Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load?Tumor. Ann Thorac Surg. 2017 Apr; 103(4):1340-1349.
Score: 0.122
-
Stachler MD, Taylor-Weiner A, Peng S, McKenna A, Agoston AT, Odze RD, Davison JM, Nason KS, Loda M, Leshchiner I, Stewart C, Stojanov P, Seepo S, Lawrence MS, Ferrer-Torres D, Lin J, Chang AC, Gabriel SB, Lander ES, Beer DG, Getz G, Carter SL, Bass AJ. Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet. 2015 Sep; 47(9):1047-55.
Score: 0.109
-
Derks S, Nason KS, Liao X, Stachler MD, Liu KX, Liu JB, Sicinska E, Goldberg MS, Freeman GJ, Rodig SJ, Davison JM, Bass AJ. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. Cancer Immunol Res. 2015 Oct; 3(10):1123-1129.
Score: 0.108
-
Bennett C, Moayyedi P, Corley DA, DeCaestecker J, Falck-Ytter Y, Falk G, Vakil N, Sanders S, Vieth M, Inadomi J, Aldulaimi D, Ho KY, Odze R, Meltzer SJ, Quigley E, Gittens S, Watson P, Zaninotto G, Iyer PG, Alexandre L, Ang Y, Callaghan J, Harrison R, Singh R, Bhandari P, Bisschops R, Geramizadeh B, Kaye P, Krishnadath S, Fennerty MB, Manner H, Nason KS, Pech O, Konda V, Ragunath K, Rahman I, Romero Y, Sampliner R, Siersema PD, Tack J, Tham TC, Trudgill N, Weinberg DS, Wang J, Wang K, Wong JY, Attwood S, Malfertheiner P, MacDonald D, Barr H, Ferguson MK, Jankowski J. BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol. 2015 May; 110(5):662-82; quiz 683.
Score: 0.107
-
Singhi AD, Foxwell TJ, Nason K, Cressman KL, McGrath KM, Sun W, Bahary N, Zeh HJ, Levy RM, Luketich JD, Davison JM. Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival. Am J Surg Pathol. 2015 Apr; 39(4):487-95.
Score: 0.107
-
Singhi AD, Seethala RR, Nason K, Foxwell TJ, Roche RL, McGrath KM, Levy RM, Luketich JD, Davison JM. Undifferentiated carcinoma of the esophagus: a clinicopathological study of 16 cases. Hum Pathol. 2015 Mar; 46(3):366-75.
Score: 0.105
-
Allum WH, Bonavina L, Cassivi SD, Cuesta MA, Dong ZM, Felix VN, Figueredo E, Gatenby PA, Haverkamp L, Ibraev MA, Krasna MJ, Lambert R, Langer R, Lewis MP, Nason KS, Parry K, Preston SR, Ruurda JP, Schaheen LW, Tatum RP, Turkin IN, van der Horst S, van der Peet DL, van der Sluis PC, van Hillegersberg R, Wormald JC, Wu PC, Zonderhuis BM. Surgical treatments for esophageal cancers. Ann N Y Acad Sci. 2014 Sep; 1325:242-68.
Score: 0.102
-
Landau MS, Hastings SM, Foxwell TJ, Luketich JD, Nason KS, Davison JM. Tumor budding is associated with an increased risk of lymph node metastasis and poor prognosis in superficial esophageal adenocarcinoma. Mod Pathol. 2014 Dec; 27(12):1578-89.
Score: 0.100
-
Davison JM, Yee M, Krill-Burger JM, Lyons-Weiler MA, Kelly LA, Sciulli CM, Nason KS, Luketich JD, Michalopoulos GK, LaFramboise WA. The degree of segmental aneuploidy measured by total copy number abnormalities predicts survival and recurrence in superficial gastroesophageal adenocarcinoma. PLoS One. 2014; 9(1):e79079.
Score: 0.098
-
Macke RA, Luketich JD, Nason KS, Schuchert MJ. Minimally invasive enucleation of a large, extensively calcified esophageal leiomyoma. J Thorac Cardiovasc Surg. 2014 Apr; 147(4):e52-4.
Score: 0.098
-
Malhotra U, Zaidi AH, Kosovec JE, Kasi PM, Komatsu Y, Rotoloni CL, Davison JM, R C, Hoppo T, Nason KS, Kelly LA, Gibson MK, Jobe BA. Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium. PLoS One. 2013; 8(11):e78343.
Score: 0.097
-
Ong CA, Shapiro J, Nason KS, Davison JM, Liu X, Ross-Innes C, O'Donovan M, Dinjens WN, Biermann K, Shannon N, Worster S, Schulz LK, Luketich JD, Wijnhoven BP, Hardwick RH, Fitzgerald RC. Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma. J Clin Oncol. 2013 Apr 20; 31(12):1576-82.
Score: 0.093
-
Radu OM, Foxwell T, Cieply K, Navina S, Dacic S, Nason KS, Davison JM. HER2 amplification in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fluorescence in situ hybridization. Am J Clin Pathol. 2012 Apr; 137(4):583-94.
Score: 0.087
-
Schuchert MJ, Abbas G, Nason KS, Pennathur A, Awais O, Santana M, Pereira R, Oostdyk A, Luketich JD, Landreneau RJ. Impact of anastomotic leak on outcomes after transhiatal esophagectomy. Surgery. 2010 Oct; 148(4):831-8; discussion 838-40.
Score: 0.078
-
Qureshi I, Nason KS, Luketich JD. Is minimally invasive esophagectomy indicated for cancer? Expert Rev Anticancer Ther. 2008 Sep; 8(9):1449-60.
Score: 0.068
-
Van Der Kraak L, Goel G, Ramanan K, Kaltenmeier C, Zhang L, Normolle DP, Freeman GJ, Tang D, Nason KS, Davison JM, Luketich JD, Dhupar R, Lotze MT. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. J Immunother Cancer. 2016; 4:65.
Score: 0.030
-
Macke RA, Nason KS, Mukaisho K, Hattori T, Fujimura T, Sasaki S, Oyama K, Miyashita T, Ohta T, Miwa K, Gibson MK, Zaidi A, Malhotra U, Atasoy A, Foxwell T, Jobe B. Barrett's esophagus and animal models. Ann N Y Acad Sci. 2011 Sep; 1232:392-400.
Score: 0.021